Summit Therapeutics Maintained at Equal-Weight by Barclays
Barclays analyst continued to rate Summit Therapeutics (NASDAQ:SMMT) with an Equal-Weight rating.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.